JP4694841B2 - ビグアニドおよびチアゾリジンジオン誘導体を含有する多段階製剤 - Google Patents

ビグアニドおよびチアゾリジンジオン誘導体を含有する多段階製剤 Download PDF

Info

Publication number
JP4694841B2
JP4694841B2 JP2004537943A JP2004537943A JP4694841B2 JP 4694841 B2 JP4694841 B2 JP 4694841B2 JP 2004537943 A JP2004537943 A JP 2004537943A JP 2004537943 A JP2004537943 A JP 2004537943A JP 4694841 B2 JP4694841 B2 JP 4694841B2
Authority
JP
Japan
Prior art keywords
cellulose
tablet
metformin
pioglitazone
coating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2004537943A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006502187A5 (https=
JP2006502187A (ja
Inventor
コシトプラパ、アンチャリー
ナンギア、アビナッシュ
カーディナル、ジョン
ゴールドファーブ、ローバート、アイ
Original Assignee
アンドルックス ラボズ リミテッド ライアビリティ カンパニー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アンドルックス ラボズ リミテッド ライアビリティ カンパニー filed Critical アンドルックス ラボズ リミテッド ライアビリティ カンパニー
Publication of JP2006502187A publication Critical patent/JP2006502187A/ja
Publication of JP2006502187A5 publication Critical patent/JP2006502187A5/ja
Application granted granted Critical
Publication of JP4694841B2 publication Critical patent/JP4694841B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2004537943A 2002-09-20 2003-09-19 ビグアニドおよびチアゾリジンジオン誘導体を含有する多段階製剤 Expired - Fee Related JP4694841B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US41218102P 2002-09-20 2002-09-20
US41218002P 2002-09-20 2002-09-20
US60/412,180 2002-09-20
US60/412,181 2002-09-20
PCT/US2003/029292 WO2004026241A2 (en) 2002-09-20 2003-09-19 Multistage formulation containing a biguanide and thiazolidindione derivatives

Publications (3)

Publication Number Publication Date
JP2006502187A JP2006502187A (ja) 2006-01-19
JP2006502187A5 JP2006502187A5 (https=) 2006-06-15
JP4694841B2 true JP4694841B2 (ja) 2011-06-08

Family

ID=32033587

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004537943A Expired - Fee Related JP4694841B2 (ja) 2002-09-20 2003-09-19 ビグアニドおよびチアゾリジンジオン誘導体を含有する多段階製剤

Country Status (8)

Country Link
EP (2) EP1539144B1 (https=)
JP (1) JP4694841B2 (https=)
KR (4) KR20100137023A (https=)
CN (2) CN101623274B (https=)
AU (1) AU2003272504A1 (https=)
CA (1) CA2499597C (https=)
ES (1) ES2529180T3 (https=)
WO (1) WO2004026241A2 (https=)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8323692B2 (en) * 2002-02-21 2012-12-04 Valeant International Bermuda Controlled release dosage forms
US7785627B2 (en) * 2002-09-20 2010-08-31 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US9060941B2 (en) 2002-09-20 2015-06-23 Actavis, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
MXPA05007883A (es) * 2003-01-29 2005-09-21 Takeda Pharmaceutical Proceso para producir una preparacion recubierta.
PE20061245A1 (es) * 2005-03-30 2007-01-06 Generex Pharm Inc Composiciones para la transmision transmucosa oral de la metformina
CN101365432B (zh) * 2005-12-16 2011-06-22 默沙东公司 二肽基肽酶-4抑制剂与二甲双胍的组合的药物组合物
US8747897B2 (en) * 2006-04-27 2014-06-10 Supernus Pharmaceuticals, Inc. Osmotic drug delivery system
MY146781A (en) 2006-05-23 2012-09-28 Takeda Pharmaceutical Oral preparation comprising pioglitazone
DE102008059206A1 (de) * 2008-11-27 2010-06-10 Bayer Schering Pharma Aktiengesellschaft Pharmazeutische Darreichungsform enthaltend Nifedipin oder Nisoldipin und einen Angiotensin-II Antagonisten und/oder ein Diuretikum
US9416098B2 (en) 2010-01-06 2016-08-16 Immunomet Therapeutics Inc. Biguanide derivative, a preparation method thereof and a pharmaceutical composition containing the biguanide derivative as an active ingredient
CA2802335A1 (en) * 2010-06-22 2011-12-29 Twi Pharmaceuticals, Inc. Controlled release compositions with reduced food effect
EP2611434A1 (en) 2010-09-01 2013-07-10 Lupin Limited Pharmaceutical composition comprising metformin and pioglitazone
CN102008472B (zh) * 2010-10-18 2012-08-22 中国科学院上海药物研究所 一种复方盐酸吡格列酮/盐酸二甲双胍双层渗透泵控释制剂及其制备方法
CN101984974B (zh) * 2010-11-15 2013-04-17 山东新华制药股份有限公司 一种用于治疗2型糖尿病的药物组合物的制备方法
CN105663130B (zh) * 2011-04-15 2019-08-09 江苏豪森药业集团有限公司 一种具有第一和第二活性药物的制剂
AU2012326976B2 (en) 2011-10-21 2017-08-17 Takeda Pharmaceutical Company Limited Sustained-release preparation
UY35006A (es) * 2012-09-06 2014-03-31 Bayer Healthcare Llc Composición farmacéutica recubierta que contiene regorafenib
CN102920704A (zh) * 2012-11-05 2013-02-13 上海现代药物制剂工程研究中心有限公司 含有双胍和噻唑烷二酮衍生物的药物制剂
WO2014184742A1 (en) 2013-05-13 2014-11-20 Ranbaxy Laboratories Limited Pharmaceutical compositions containing a biguanide and a low dose antidiabetic agent
CN106458868A (zh) 2014-04-17 2017-02-22 伊谬诺米特医疗有限公司 胍化合物及其用途
EP3025707A1 (en) * 2014-11-27 2016-06-01 Arven Ilac Sanayi Ve Ticaret A.S. A multilayer tablet comprising metformin and pioglitazone
CN104473894A (zh) * 2014-12-18 2015-04-01 浙江华海药业股份有限公司 一种盐酸吡格列酮载药包衣制剂及其制备方法
CN106137999A (zh) * 2015-03-31 2016-11-23 深圳翰宇药业股份有限公司 一种复方吡格列酮二甲双胍缓释片及其制备方法
KR101750690B1 (ko) * 2015-10-28 2017-06-27 주식회사 종근당 메트포르민 및 로베글리타존을 포함하는 약제학적 조성물
CN108478537A (zh) * 2018-05-03 2018-09-04 南京易亨制药有限公司 一种含普瑞巴林的单室渗透泵控释片剂
WO2021242040A1 (ko) * 2020-05-29 2021-12-02 한국유나이티드제약 주식회사 삼투압에 의해 방출 조절되는 서방성 메트포르민 코팅 정제 및 이의 제조방법
US11684596B2 (en) * 2020-09-22 2023-06-27 Elite Pharmaceuticals Solution Inc. Antidiabetic pharmaceutical compositions and preparation method thereof

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
FR2243684B1 (https=) 1973-09-19 1977-01-28 Semb
US4080472A (en) 1974-03-22 1978-03-21 Societe D'etudes Et D'exploitation De Marques Et Brevets S.E.M.S. Metformin 2-(p-chlorophenoxy)-2-methylpropionate
US3952741A (en) 1975-01-09 1976-04-27 Bend Research Inc. Controlled release delivery system by an osmotic bursting mechanism
US4034758A (en) 1975-09-08 1977-07-12 Alza Corporation Osmotic therapeutic system for administering medicament
US4036228A (en) 1975-09-11 1977-07-19 Alza Corporation Osmotic dispenser with gas generating means
US4077407A (en) 1975-11-24 1978-03-07 Alza Corporation Osmotic devices having composite walls
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4522625A (en) 1982-09-29 1985-06-11 Alza Corporation Drug dispenser comprising wall formed of semipermeable member and enteric member
US4783337A (en) 1983-05-11 1988-11-08 Alza Corporation Osmotic system comprising plurality of members for dispensing drug
US4612008A (en) 1983-05-11 1986-09-16 Alza Corporation Osmotic device with dual thermodynamic activity
US4587117A (en) 1983-06-06 1986-05-06 Alza Corporation Medical device for delivering drug to pH environments greater than 3.5
US4777049A (en) 1983-12-01 1988-10-11 Alza Corporation Constant release system with pulsed release
US4851229A (en) 1983-12-01 1989-07-25 Alza Corporation Composition comprising a therapeutic agent and a modulating agent
AR240698A1 (es) 1985-01-19 1990-09-28 Takeda Chemical Industries Ltd Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales
US4892739A (en) 1988-04-25 1990-01-09 Ciba-Geigy Corporation Osmotic continuous dispensing oral delivery system containing a pharmaceutically acceptable active agent having a improved core membrane adhesion properties
US5071607A (en) 1990-01-31 1991-12-10 Alza Corporatino Method and apparatus for forming a hole in a drug dispensing device
US5178866A (en) 1990-03-23 1993-01-12 Alza Corporation Dosage form for delivering drug to the intestine
US5178867A (en) 1991-08-19 1993-01-12 Alza Corporation Dosage form for delivering drug in short-time period
DE4432757A1 (de) 1994-09-14 1996-03-21 Boehringer Mannheim Gmbh Pharmazeutische Zubereitung enthaltend Metformin und Verfahren zu deren Herstellung
TWI238064B (en) * 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
US5859037A (en) 1997-02-19 1999-01-12 Warner-Lambert Company Sulfonylurea-glitazone combinations for diabetes
US6011049A (en) 1997-02-19 2000-01-04 Warner-Lambert Company Combinations for diabetes
US6153632A (en) 1997-02-24 2000-11-28 Rieveley; Robert B. Method and composition for the treatment of diabetes
ATE355840T1 (de) * 1997-06-18 2007-03-15 Smithkline Beecham Plc Behandlung der diabetes mit thiazolidindione und metformin
GB9715295D0 (en) * 1997-07-18 1997-09-24 Smithkline Beecham Plc Novel method of treatment
FR2772615B1 (fr) * 1997-12-23 2002-06-14 Lipha Comprime multicouche pour la liberation instantanee puis prolongee de substances actives
EP1063973B1 (en) 1998-03-19 2016-11-16 Bristol-Myers Squibb Company Biphasic controlled release delivery system for high solubility pharmaceuticals and method
US6099859A (en) * 1998-03-20 2000-08-08 Andrx Pharmaceuticals, Inc. Controlled release oral tablet having a unitary core
US6099862A (en) * 1998-08-31 2000-08-08 Andrx Corporation Oral dosage form for the controlled release of a biguanide and sulfonylurea
US7374779B2 (en) * 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
US6290699B1 (en) 1999-07-07 2001-09-18 Uab Research Foundation Ablation tool for forming lesions in body tissue
AR030920A1 (es) * 1999-11-16 2003-09-03 Smithkline Beecham Plc Composiciones farmaceuticas para el tratamiento de la diabetes mellitus y condiciones asociadas con la diabetes mellitus, y procedimientos para preparar dichas composiciones
AU1403501A (en) * 1999-11-16 2001-05-30 Smithkline Beecham Plc Novel composition and use
EP1239839A2 (en) * 1999-12-23 2002-09-18 Pfizer Products Inc. Hydrogel-driven layered drug dosage form comprising sertraline
SE0001151D0 (sv) * 2000-03-31 2000-03-31 Amarin Dev Ab Method for producing a controlled-release composition
US6524621B2 (en) 2000-05-01 2003-02-25 Aeropharm Technology Inc. Core formulation
US6780432B1 (en) * 2000-05-01 2004-08-24 Aeropharm Technology, Inc. Core formulation
US6451342B2 (en) 2000-05-01 2002-09-17 Aeropharm Technology Incorporated Core formulation comprised of troglitazone and a biguanide
DE10025946A1 (de) * 2000-05-26 2001-11-29 Gruenenthal Gmbh Wirkstoffkombination
US20030086972A1 (en) * 2000-08-09 2003-05-08 Appel Leah E. Hydrogel-driven drug dosage form
US20030224046A1 (en) * 2002-06-03 2003-12-04 Vinay Rao Unit-dose combination composition for the simultaneous delivery of a short-acting and a long-acting oral hypoglycemic agent

Also Published As

Publication number Publication date
KR20130039344A (ko) 2013-04-19
KR101363679B1 (ko) 2014-02-14
HK1136780A1 (en) 2010-07-09
AU2003272504A1 (en) 2004-04-08
CA2499597C (en) 2012-01-17
CN1681496A (zh) 2005-10-12
KR20100137023A (ko) 2010-12-29
EP2604266A1 (en) 2013-06-19
CN101623274B (zh) 2012-06-27
CA2499597A1 (en) 2004-04-01
KR20120034211A (ko) 2012-04-10
HK1078783A1 (zh) 2006-03-24
ES2529180T3 (es) 2015-02-17
CN100544717C (zh) 2009-09-30
EP1539144A2 (en) 2005-06-15
EP1539144B1 (en) 2014-12-24
AU2003272504A8 (en) 2004-04-08
JP2006502187A (ja) 2006-01-19
KR20050053677A (ko) 2005-06-08
EP1539144A4 (en) 2010-06-09
WO2004026241A2 (en) 2004-04-01
WO2004026241A3 (en) 2004-06-10
CN101623274A (zh) 2010-01-13

Similar Documents

Publication Publication Date Title
JP4694841B2 (ja) ビグアニドおよびチアゾリジンジオン誘導体を含有する多段階製剤
US8309125B2 (en) Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US8668931B2 (en) Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
CA2601501C (en) Novel pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
HK1078783B (en) Multistage formulation containing a biguanide and thiazolidindione derivatives
HK1136780B (en) Multistage formulation containing a biguanide and thiazolidindione derivatives

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060323

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060420

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090908

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20091204

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20091211

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20091225

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100114

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100202

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20110203

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20110224

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140304

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees